1. Home
  2. WINT vs BBLG Comparison

WINT vs BBLG Comparison

Compare WINT & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • BBLG
  • Stock Information
  • Founded
  • WINT 1992
  • BBLG 2004
  • Country
  • WINT United States
  • BBLG United States
  • Employees
  • WINT N/A
  • BBLG N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • BBLG Industrial Specialties
  • Sector
  • WINT Health Care
  • BBLG Health Care
  • Exchange
  • WINT Nasdaq
  • BBLG Nasdaq
  • Market Cap
  • WINT 2.0M
  • BBLG 2.4M
  • IPO Year
  • WINT 1995
  • BBLG N/A
  • Fundamental
  • Price
  • WINT $0.12
  • BBLG $1.18
  • Analyst Decision
  • WINT Hold
  • BBLG
  • Analyst Count
  • WINT 1
  • BBLG 0
  • Target Price
  • WINT $7.00
  • BBLG N/A
  • AVG Volume (30 Days)
  • WINT 7.3M
  • BBLG 249.1K
  • Earning Date
  • WINT 11-27-2024
  • BBLG 02-19-2025
  • Dividend Yield
  • WINT N/A
  • BBLG N/A
  • EPS Growth
  • WINT N/A
  • BBLG N/A
  • EPS
  • WINT N/A
  • BBLG N/A
  • Revenue
  • WINT N/A
  • BBLG N/A
  • Revenue This Year
  • WINT N/A
  • BBLG N/A
  • Revenue Next Year
  • WINT N/A
  • BBLG N/A
  • P/E Ratio
  • WINT N/A
  • BBLG N/A
  • Revenue Growth
  • WINT N/A
  • BBLG N/A
  • 52 Week Low
  • WINT $0.11
  • BBLG $0.80
  • 52 Week High
  • WINT $14.75
  • BBLG $4.74
  • Technical
  • Relative Strength Index (RSI)
  • WINT 15.60
  • BBLG 57.46
  • Support Level
  • WINT $0.21
  • BBLG $1.03
  • Resistance Level
  • WINT $0.33
  • BBLG $1.29
  • Average True Range (ATR)
  • WINT 0.03
  • BBLG 0.10
  • MACD
  • WINT 0.00
  • BBLG 0.03
  • Stochastic Oscillator
  • WINT 2.15
  • BBLG 69.44

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About BBLG Bone Biologics Corp

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Share on Social Networks: